EQS-News: Gerresheimer AG / Key word(s): Regulatory ApprovalGerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*13.10.2025 / 10:00 CET/CESTThe issuer is solely responsible for the content of this announcement. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. First products of Lasix ONYU are expected to be available on the market already in 2025. “Lasix ONYU has the potential to be transformative in the care of patients experiencing worsening heart failure due to fluid overload.